Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC 50 of 0.052 μM and an EC 50 of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research.
性状
Solid
IC50 & Target[1][2]
IC50: 0.052 μM (FASN)
体外研究(In Vitro)
Denifanstat (compound 152) is a potent FASN inhibitor. Fatty Acid Synthase (FASN) inhibition prevents palmitoylation of SARS-CoV2 spike protein. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
ClinicalTrial
参考文献
[1]. Minhyoung Lee, et al. Fatty Acid Synthase inhibition prevents palmitoylation of SARS-CoV2 Spike Protein and improves survival of mice infected with murine hepatitis virus. BioRxiv, December 21, 2020.[2]. Johan D., et al. Heterocyclic modulators of lipid synthesis. WO2012122391A1.
溶解度数据
In Vitro: DMSO : 100 mg/mL (227.51 mM; Need ultrasonic)配制储备液